
BioNTech reveals promising late-stage cancer drug data at ASCO 2026, advancing treatments for lung and ovarian cancers.
BioNTech presented encouraging clinical data for its late-stage cancer drug candidates Pumitamig and Gotistobart at the ASCO 2026 meeting. Pumitamig showed promising anti-tumor activity in a Phase 2/3 study for first-line treatment of non-small cell ...
